Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Richard A. Larson, Dong-Wook Kim, MD PhD, Surapol Issaragrilsil, MD, Philipp le Coutre, MD, Pedro Enrique Dorlhiac Llacer, Gabriel Etienne, MD PhD, Richard E. Clark, MD, Ian Flinn, Hirohisa Nakamae, Andreas Hochhaus, MD, Giuseppe Saglio, MD, Hagop M. Kantarjian, Breanne Donohue, PharmD, Weiping Deng, PhD, Hans D. Menssen, MD PhD, Timothy P. Hughes, MD

Blood (2014) 124 (21): 4541.

https://doi.org/10.1182/blood.V124.21.4541.4541

Published: 2014

Journal Articles

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Timothy P. Hughes, Jeffrey H. Lipton, Nelson Spector, Francisco Cervantes, Ricardo Pasquini, Nelma Cristina D. Clementino, Pedro Enrique Dorlhiac Llacer, Anthony P. Schwarer, Francois-Xavier Mahon, Delphine Rea, Susan Branford, Das Purkayastha, LaTonya Collins, Tomasz Szczudlo, Brian Leber

Blood (2014) 124 (5): 729–736.

https://doi.org/10.1182/blood-2013-12-544015

Published: 2014

Journal Articles

Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib

H. Jean Khoury, Dong-Wook Kim, MD, Andrey Zaritskey, Carlo Gambacorti-Passerini, Andreas Hochhaus, Juan Navarro, Aaron P. Rapoport, Pedro Enrique Dorlhiac-Llacer, Maria Zanichelli, Virginia Kelly, Nadine Besson, Trevor McMullan, Hagop M. Kantarjian, Jorge E. Cortes

Blood (2010) 116 (21): 892.

https://doi.org/10.1182/blood.V116.21.892.892

Published: 2010

Journal Articles

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

Andreas Hochhaus, MD, Giuseppe Saglio, MD, PhD, Richard A. Larson, MD, Dong-Wook Kim, MD, PhD, Ian W. Flinn, MD, PhD, Yeow-Tee Goh, MBBS, MD, Pedro Enrique Dorlhiac-Llacer, MD, Kimmo Porkka, MD, PhD, Mineo Kurokawa, MD, PhD, Carmino DeSouza, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Ariful Haque, Hagop Kantarjian, MD, Timothy P. Hughes, MD, MBBS

Blood (2010) 116 (21): 3431.

https://doi.org/10.1182/blood.V116.21.3431.3431

Published: 2010

Journal Articles

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Anna Turkina, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Si-Tien Wang, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 3286.

https://doi.org/10.1182/blood.V114.22.3286.3286

Published: 2009

Journal Articles

Outcome of Patients with Philadelphia Positive Chronic Myeloid Leukemia Post Imatinib Failure: Prognostic Significance of ABL Mutation and Additional Clonal Abnormality.

Monika Conchon, Patricia B Ferreira, Mafalda MY Novaes, Luciana Nardinelli, Mariana Serpa, Pedro Enrique Dorlhiac-Llacer, Dalton FA Chamone, Cristina A Kumeda, Israel Bendit

Blood (2009) 114 (22): 4673.

https://doi.org/10.1182/blood.V114.22.4673.4673

Published: 2009

Journal Articles

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Franck Emmanuel Nicolini, MD, PhD, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A. Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Christine Bieri, MBA, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 2201.

https://doi.org/10.1182/blood.V114.22.2201.2201

Published: 2009

NARROW

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Outcome of Patients with Philadelphia Positive Chronic Myeloid Leukemia Post Imatinib Failure: Prognostic Significance of ABL Mutation and Additional Clonal Abnormality.

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Outcome of Patients with Philadelphia Positive Chronic Myeloid Leukemia Post Imatinib Failure: Prognostic Significance of ABL Mutation and Additional Clonal Abnormality.

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only